New pill shows promise for Hard-to-Treat blood cancers

NCT ID NCT03913949

Ongoing Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take the drug daily in 28-day cycles. This is a Phase 1 study, so it is primarily looking at safety and how the body processes the drug, not yet whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-2575 (an experimental oral drug)
What this could lead to: If successful, this could lead to a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 74 participants, focused on safety and dosing. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma mantle cell lymphoma non-Hodgkin lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Anhui Procincial hospital

Hefei, Anhui, China
Blood Diseases Hospital Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300020, China
Henan Provincial Oncology Hospital

Zhengzhou, Henan, China
The First Affiliated Hospital, Zhejiang University School of Medicin

Hangzhou, Zhejiang, China
Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.